On Dec. 10, 2004, a National Cancer Institute supported study determined that a new molecular test byin collaboration with the National Surgical Adjuvant Breast and Bowel Project and Genomic Health, can predict the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy. The test is based on levels of expression (increased or decreased) of a panel of cancer-related genes that is used to predict whether estrogen-dependent breast cancer will come back.